Janoshik and Finnrick Data Reveal Key Trends in Peptide Product Purity and Brand Comparison
Abstract: Janoshik and Finnrick data reveal critical purity disparities across peptide brands, with top-tier manufacturers achieving >99% via HPLC/MS verification versus sub-95% for unverified sources. Market trends show rising demand for GMP-certified products, particularly in research-grade GLP-1 agonists and growth hormone secretagogues. Brand comparison highlights superior stability in lyophilized formulations from ISO-accredited facilities. Key selection criteria include third-party COA validation, batch-specific purity profiles, and cold-chain logistics compliance. The analysis underscores that regulatory-compliant peptides with documented synthesis methods outperform generic alternatives in bioactivity and shelf-life, shaping industry consolidation toward certified suppliers.